NorthWest Biotherapeutics Inc (NWBO)

[apmarshall]

IDH Mutation Question

I am a long-time long on the stock but post rarely. My question relates to the change in definition of glioblastoma to exclude IDH positive patients.

NWBO has stated that it has had to reach back and test patient samples from the P3 study to determine their IDH mutation status because the significance of the IDH mutation wasn't known in the early years of the study.

Assuming I have all of this correct, does the change in definition of glioblastoma make it difficult to compare historical control data in past trials, which presumably lack IDH mutation data, against our upcoming trial data?